DDInter1744 DDInter596
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Daunorubicin
Daunorubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Tamoxifen {u} (Compound) treats {v} (Disease) pancreatic cancer
pancreatic cancer {u} (Disease) is treated by {v} (Compound) Doxorubicin
Tamoxifen {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Tamoxifen {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) DHCR7
DHCR7 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Tamoxifen {u} (Compound) upregulates {v} (Gene) SESN1
SESN1 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Tamoxifen {u} (Compound) binds {v} (Gene) CES1
CES1 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Tamoxifen {u} (Compound) downregulates {v} (Gene) PSMB10
PSMB10 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Tamoxifen {u} (Compound) downregulates {v} (Gene) CCNA2
CCNA2 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Tamoxifen {u} (Compound) upregulates {v} (Gene) DDIT4
DDIT4 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin (Compound) resembles Doxorubicin (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) resembles Doxorubicin (Compound)
Tamoxifen (Compound) treats pancreatic cancer (Disease) and pancreatic cancer (Disease) is treated by Doxorubicin (Compound)
Tamoxifen (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxorubicin (Compound)
Tamoxifen (Compound) binds DHCR7 (Gene) and Tamoxifen (Compound) upregulates DHCR7 (Gene) and DHCR7 (Gene) is bound by Doxorubicin (Compound)
Tamoxifen (Compound) upregulates SESN1 (Gene) and SESN1 (Gene) is upregulated by Doxorubicin (Compound)
Tamoxifen (Compound) binds CES1 (Gene) and CES1 (Gene) is upregulated by Doxorubicin (Compound)
Tamoxifen (Compound) downregulates PSMB10 (Gene) and PSMB10 (Gene) is upregulated by Doxorubicin (Compound)
Tamoxifen (Compound) downregulates CCNA2 (Gene) and CCNA2 (Gene) is downregulated by Doxorubicin (Compound)
Tamoxifen (Compound) upregulates DDIT4 (Gene) and DDIT4 (Gene) is downregulated by Doxorubicin (Compound)